IPSS-M Scoring System
IPSS-M Scoring System
The IPSS-M is the newest MDS prognosis model that combines genomic profiling with the hematologic and cytogenetic parameters from the IPSS-R model, improving the risk stratification of patients with MDS. This is a valuable tool for clinical decision-making, offering the prospect of tailoring diagnosis and therapeutic interventions to each patient’s molecular profile.
The IPSS-M uses the following
information to determine your
risk score.
| Your age | Absolute Neutrophil count |
| Hemoglobin | % Bone marrow blasts |
| Platelet count | IPSS-R Cytogenetic Risk Categories |
| Next generation sequencing or other molecular testing methods. | |
Next generation sequencing (NGS) or other molecular testing methods are used to determine your gene mutation status. The status of these genes, non-mutated, mutated, or not assessed, impacts your risk score.
| TP53 – # of mutations | RUNX1 | U2AF1 |
| TP53 loss of heterozygosity | NRAS | SRSF2 |
| MLLPTD | ETV6 | DNMT3A |
| FLT3ITD+TKD | IDH2 | ASXL1 |
| SF3B1-5q | CBL | KRAS |
| NPM1 | EZH2 | SF3B1α |
The IPSS-M calculator also incorporates the number of residual gene mutations with adverse effects, however, these are weighted lower based on statistical measures.The status of these genes, non-mutated, mutated, or not assessed, also impacts your risk score.
| BCOR | GNB1 | PRPF8 |
| BCORL1 | IDH1 | PTPN11 |
| CEBPA | NF1 | SETBP1 |
| ETNK1 | PHF6 | STAG2 |
| GATA2 | PPM1D | WT1 |
The collective data are used to generate one of six overall risk scores to estimate survival and median risk of AML transformation (AML-t): VL = Very Low; L = Low; ML = Moderate Low; MH = Moderate High; H = High; VH = Very High.
| Six IPSS-M Risk Categories (N=2701) | VL | L | ML | MH | H | VH | |
|---|---|---|---|---|---|---|---|
| Characteristics/Values | N per group | 381 | 889 | 302 | 281 | 379 | 469 |
| Distribution by risk group (%) | 14% | 33% | 11% | 11% | 14% | 17% | |
| Median Leukemia Free Survival (Years) 25-75% range | 9.7 | 5.9 | 4.5 | 2.3 | 1.5 | 0.76 | |
| Median Overall Survival (Years) 25-75% range | 10.6 | 6.0 | 4.6 | 2.8 | 1.7 | 1.0 | |
| AML Transformation (AML-t)% | Time from MDS Diagnosis | ||||||
| % by year 1 | 0.0 | 1.7 | 4.9 | 9.5 | 14.3 | 28.2 | |
| % by year 2 | 1.2 | 3.4 | 8.8 | 14.0 | 21.2 | 38.6 | |
| % by year 4 | 2.8 | 5.1 | 11.4 | 18.9 | 29.2 | 42.8 | |
| Deal without AML % | Time from MDS Diagnosis | ||||||
| % by year 1 | 2.2 | 8.5 | 12.0 | 18.0 | 19.3 | 30.6 | |
| % by year 2 | 7.0 | 16.2 | 19.8 | 31.1 | 39.8 | 45.6 | |
| % by year 4 | 15.9 | 29.5 | 33.6 | 51.1 | 54.2 | 51.3 | |